Talking KRAS-Targeted Therapy in NSCLC With Dr. Levy

Season 3 Episode 31  ·  Aug 20, 2020, 07:22 PM

Headliner
Share
Subscribe

In our exclusive interview, Dr. Levy discusses the challenges of targeting KRAS and highlighted some of the investigational agents directed toward KRAS G12C mutations that have emerged in the NSCLC pipeline.

Share
Subscribe
Next
Talking Tumors: Evaluating Early-Stage Breast Cancer Cases in the COVID-19 Era
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air